Self-tests for HIV in South Africa are currently unregulated. Gaps in law and policy have created a legal loophole where such tests could effectively be sold in supermarkets, but not in pharmacies. At the same time, South Africa lacks an effective regulating mechanism for diagnostic tests, which brings the quality and reliability of all self- tests into question. The authors argue for greater access to, and availability of, quality HIV self-tests, despite drawbacks like increased risk of unmanaged anxiety with potential for suicide if a positive result is given, lack of counselling and possible family coercion into testing. They argue that self-testing will lead to earlier diagnosis of HIV status and earlier enrolment into treatment, and decrease the costs associated with traditional voluntary counselling and testing, and allay fears about stigma and confidentiality when testing in public facilities.
Equity and HIV/AIDS
Doubts have been cast about the ability of Home-Based HIV Counseling and Testing (HBHCT) to adhere to ethical practices including consent, confidentiality, and access to HIV care post-test. This study explored client experiences in relation these ethical issues. Researchers conducted 395 individual interviews in Kumi district, Uganda, where teams providing HBHCT had visited 6–12 months prior to the interviews. They found that 95% of respondents had ever tested (average for Uganda was 38%). Among those who were approached by HBHCT providers, 98% were informed of their right to decline HIV testing. Most respondents were counseled individually, but 69% of the married/cohabiting were counseled as couples. Most respondents (94%) were satisfied with the information given to them and the interaction with the HBHCT providers. These findings show a very high uptake of HIV testing and satisfaction with HBHCT, a large proportion of married respondents tested as couples, and high disclosure rates. HBHCT can play a major role in expanding access to testing and overcoming disclosure challenges. However, access to HIV services post-test may require attention.
The International Rescue Committee (IRC) in Northern Uganda has begun operating home-based HIV counselling and testing in ten camps for internally displaced persons in the Kitgum region. The IRC intends to reach about 100,000 camp residents in their homes. HIV has spread rapidly in the region because the situation in the camps has adversely changed the way people behave.
The persistent and increasing outbreaks of violence against members of the gay community in Africa are jeopardising efforts undertaken to combat HIV, both within this group and across the population as a whole, AIDS activists warned at a recent meeting in Limbé, Cameroon. The extreme vulnerability of members of the gay community to HIV on the continent was highlighted during a meeting initiated by the French non-governmental organisation, AIDES, and its partners, which took place at the beginning of July in the south west of Cameroon. The meeting brought together many AIDS activists from Francophone African countries. On average it is estimated that HIV infection rates amongst MSM (men who have sex with men) are four to five times higher than the population overall.
Southern and eastern Africa, with 6.2% of the world’s population, bear a disparate half of the world’s HIV infection burden and would benefit greatly from inexpensive innovations aimed at curtailing the epidemic. A recent modelling study showed that introducing a partially (30%) effective vaccine for HIV in resource-limited settings such as southern Africa would result in an estimated 67% reduction in HIV incidence compared to a non-vaccine scenario. As sub-Saharan Africa has the highest incidence of HIV infection in the world, that the introduction of a vaccine with only partial efficacy could have such a dramatic effect, despite the existing availability of comprehensive prevention methods, is argued by the authors to be strongly persuasive for the pursuit of a vaccine-based approach. Whilst there is great optimism that increasing access to antiretroviral treatment in the region will reduce infection incidence, there is also recognition that epidemic control will not be achieved without a substantial and sustained scale-up of additional primary prevention resources. There are challenges to HIV prevention in resource-limited settings that a vaccine alone is seen to be well positioned to meet. These include the rate of HIV infections and the scale and complexity of the HIV epidemic in the region, juxtaposed with ailing health systems ill equipped to respond effectively. Challenges with antiretroviral drug therapy adherence, poor linkage to care following diagnosis, multiple and diverse vulnerable populations who require population-specific services (such as women, adolescents, and men who have sex with men, stigma, and discrimination, as well as generally limited health care facilities and health personnel impair the region’s capacity to manage the scale of the epidemic. Even with the success of pre-exposure prophylaxis demonstration projects and the encouraging results emerging, the extent of protection relies on fidelity to adherence, continuous uninterrupted access, and sustainable resources for provision. It is well documented that in resource-restricted areas, where education levels and access to health care are low, reliance on behavioural and structural support is also an enormous challenge. A vaccine, even if partially effective, is argued by the authors to be a way of filling these prevention gaps in a cost-effective manner. Whilst countries in this region must find ways to access all the available opportunities that the modern HIV prevention toolkit has on offer, such a vaccine is seen to potentially change the prevention landscape.
Hopes that a South African-developed vaginal gel containing tenofovir would protect women against HIV were dashed after a major new study found that it did not work. Scientists had been optimistic that the microbicide would protect millions of women from HIV, after a phase 2 study of 900 women in KwaZulu-Natal found it reduced the risk of getting the virus by 39%. The development was hailed as a breakthrough, though the scientists who led the work were careful to emphasise that further research was needed to replicate the findings. At that stage, 11 other trials testing six other products had failed. The findings had a wide margin of error, with the efficacy of HIV protection estimated to lie between 6% and 60%. A much larger Follow-on African Consortium for Tenofovir Studies (FACTS) 001 trial was launched in 2011 to confirm its findings. The consortium scientists announced at the annual Conference on Retroviruses and Opportunistic Infections in Seattle, however, that the tenofovir-containing microbicide provided to 2,059 women aged between 18 years and 30 years did not protect them from HIV.
Adolescents (aged 10–18) were systematically recruited from acute admissions to the two public hospitals in Harare, Zimbabwe, to answer a questionnaire and undergo standard investigations including HIV testing, with consent. Pre-set case-definitions defined cause of admission and underlying chronic conditions. Participation was 94%. In total, 139 (46%) of 301 participants were HIV-positive, but only four were herpes simplex virus-2 (HSV-2) positive. Age and sex did not differ by HIV status, but HIV-infected participants were significantly more likely to be stunted, have pubertal delay, and be maternal orphans or have an HIV-infected mother. In conclusion, HIV is the commonest cause of adolescent hospitalisation in Harare, mainly due to adult-spectrum opportunistic infections plus a high burden of chronic complications of paediatric HIV and AIDS. Low HSV-2 prevalence and high maternal orphanhood rates provide further evidence of long-term survival following mother-to-child transmission. Better recognition of this growing phenomenon is needed to promote earlier HIV diagnosis and care.
This paper presents how the changes wrought by HIV have affected research, clinical practice, and policy. The AIDS epidemic provided the foundation for a revolution that upended traditional approaches to international health, replacing them with innovative global approaches to disease. Over the past half-century, historians have used episodes of epidemic disease to investigate scientific, social, and cultural change. Underlying this approach is the recognition that disease, and especially responses to epidemics, offers fundamental insights into scientific and medical practices, as well as social and cultural values.
Lost earnings attributable to HIV and AIDS as a result of either death or inability to work have declined significantly globally as countries scale up antiretroviral therapy. In 2005 HIV and AIDS were believed to have resulted in about $17bn in lost income, but the figure is projected to fall to $7.2bn in 2020. A study released by the International Labour Organisation shows that the number of employees living with the virus and unable to work has fallen "dramatically" since 2005. South Africa has the biggest HIV epidemic in the world with more than 7-million people living with the virus in 2016 and a stubbornly high rate of new infections. The country also has the largest antiretroviral treatment programme, which has increased life expectancy from 61 years in 2010 to 67 in 2015. The Employee Assistance Professionals Association’s Dr Dennis Cronson said there had been a great improvement in the effect of the virus on workers, especially in South Africa. "Hundreds of thousands of people are on ARVs and corporate managed programmes, and it’s a major success story …. the impact on productivity and other factors have improved," Cronson said.
It is estimated that only seven percent of those with HIV/AIDS in developing countries receive any anti-retroviral (ARV) therapy. Guaranteed long-term access to affordable medicines, along with investment in public health infrastructure, is essential to tackle the pandemic. How can developing countries overcome the barriers to accessing HIV/AIDS drugs? Developing countries are currently stuck in a ‘price-infrastructure trap’: high prices for HIV/AIDS drugs reduce the possibility of extending treatment programmes and decrease government motivation to invest in much-needed public health infrastructure for HIV/AIDS. The generally limited response of these countries to the HIV/AIDS pandemic is largely due to the problem of stability of access to affordable medications.